Michelle O'Donoghue, MD, MPH is an Associate Physician in the Cardiovascular Division of Brigham and Women's Hospital and an Affiliate Physician in the Cardiovascular Division of Massachusetts General Hospital. She has been working as an investigator with the TIMI Study Group since 2005.
Dr. O'Donoghue's primary research focus is the design and conduct of multicenter clinical trials for patients with stable and unstable heart disease. She is currently the co-Principal Investigator of the global SOLID-TIMI 52 trial, the phase III randomized trial of the direct Lp-PLA2 inhibitor darapladib in patients after an acute coronary syndrome. She is currently serving as the National Lead Investigator for the LATITUDE-TIMI 60 trial, the phase III randomized trial of losmapimod in ACS patients. Prior trial leadership includes the PRINCIPLE-TIMI 44 trial (a pharmacodynamic study of prasugrel versus clopidogrel in PCI) and the LANCELOT phase II program of the PAR-1 antagonist atopaxar. She is the local Principal Investigator of the PEGASUS-TIMI 54 trial (ticagrelor in patients with a history of myocardial infarction) and the CAMELLIA-TIMI 61 trial (lorcaserin in overweight patients with cardiovascular disease or risk factors). Additional clinical research interests include the evaluation of novel antiplatelet drugs, established and novel biomarkers, the study of women and heart disease and the development of novel therapeutics in the management of acute coronary syndromes.
Dr. O'Donoghue earned her medical degree from Columbia University College of Physicians and Surgeons in New York. She completed her residency in internal medicine and fellowship in cardiovascular medicine at Massachusetts General Hospital. She subsequently completed a Masters in Public Health degree at the Harvard School of Public Health.
Christian T. Ruff, MD, MPH is currently an Associate Physician in the Cardiovascular Division at Brigham and Women's Hospital in Boston, MA, an Instructor in Medicine at Harvard Medical School, and head of the TIMI Study Group's Genetics Program. He was a lead co-investigator for the ENGAGE AF-TIMI 48 study evaluating the investigational, oral, once-daily, factor Xa inhibitor edoxaban for the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation.
Dr. Ruff graduated magna cum laude from Harvard University with a degree in neurobiology in 1998. He earned his medical degree with Alpha Omega Alpha honors at the Johns Hopkins University School of Medicine in 2003 and his Master of Public Health at the Harvard School of Public Health in 2010. Dr. Ruff completed his internal medicine residency and cardiovascular medicine fellowship at the Brigham and Women's Hospital.
Dr. Ruff is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group and serves as the Assistant Director of the Clinical Events Committee. He has led a broad array of projects, ranging from small studies of biomarkers and genetic variants to large clinical trials. Dr. Ruff has specific expertise in risk stratification in atrial fibrillation and implementation of novel antithrombotic therapy for stroke prevention. He has been selected to serve as the Chairman for the Stroke Prevention in Atrial Fibrillation Consensus Initiative for the North American Thrombosis Forum (NATF) and also serves on its Board of Directors. Dr. Ruff has authored more than 40 scholarly articles, editorials, reviews, and book chapters and has given dozens of lectures nationally and internationally. His clinical research has been published in several peer-reviewed journals, including The New England Journal of Medicine, Lancet, The Journal of the American Medical Association, American Journal of Medicine, Circulation and Nature Reviews Cardiology.
Marc P. Bonaca, MD, MPH is an Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital, an Instructor of Medicine at Harvard Medical School and an investigator at the TIMI Study Group. Dr. Bonaca earned his medical degree (M.D.) from University of Connecticut School of Medicine and a Master of Public Health (M.P.H.) from the Harvard School of Public Health. He completed his internal medicine residency and fellowships in cardiovascular medicine and vascular medicine at Brigham and Women's Hospital and is board certified in internal medicine and cardiology.
Dr. Bonaca's research interests include characterization and prediction of cardiovascular risk in patients with atherosclerotic vascular disease as well as investigation of therapies to reduce that risk. Specific disease states of interest include peripheral artery disease, stable coronary artery disease, and aortic disease. He is an active investigator in clinical trials investigating novel therapies including antithrombotic agents for the reduction of cardiovascular risk in patients with symptomatic peripheral artery disease and stable coronary disease. In addition, he is actively involved in the evaluation of established and novel biomarkers as well as clinical characteristics for risk prediction in specific patient populations. In addition to scientific investigation and clinical trial work, Dr. Bonaca leads the TIMI Safety Desk which includes 20 staff members and which is responsible for the monitoring and processing of safety data for multiple large international clinical trials.
In addition to his scientific, clinical trial, and safety responsibilities, Dr. Bonaca is an active member of the clinical staff at Brigham and Women's hospital and attends on the inpatient cardiology and cardiology/vascular medicine consult services. He maintains a regular clinic and directs the Brigham and Women's Acute Aortic Syndrome program.
Erin Bohula May, MD, DPhil is an Associate Physician in Cardiovascular Medicine at Brigham and Women's Hospital, an Instructor of Medicine at Harvard Medical School, and an Investigator at the TIMI Study Group. Dr. Bohula May earned her Doctor of Philosophy (D.Phil.) in Molecular Biology from Oxford University on a Rhodes Scholarship and her medical degree (M.D.) from Harvard Medical School. She completed her internal medicine residency and fellowships in cardiovascular medicine and critical care medicine at Brigham and Women's Hospital. She is board certified in internal medicine and cardiology and board eligible in critical care medicine.
Dr. Bohula May's research interests include the interplay of obesity, metabolic health and cardiovascular disease, evaluation of novel biomarkers and the application of innovative technologies for critically-ill cardiovascular patients. To this end, she is an investigator in a clinical trial studying the cardiovascular and metabolic impact of pharmacologic therapy for weight loss in obese or overweight individuals. In addition, she is investigating the prognostic utility of established and novel biomarkers for prediction of future cardiovascular events in multiple patient populations, including those with risk factors, stable vascular disease and acute coronary syndromes. Finally, she is studying novel, non-invasive methods of identifying and monitoring cardiogenic shock in the intensive care setting.
In addition to her scientific and trial responsibilities, Dr. Bohula May is an active member of the clinical staff at Brigham and Women's hospital and attends in the Cardiology Critical Care Unit and inpatient General Cardiology Service.